# Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

> **NCT01328249** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 81 (actual)

## Conditions studied

- HER2-normal

## Interventions

- **DRUG:** eribulin mesylate

## Key facts

- **NCT ID:** NCT01328249
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-03
- **Primary completion:** 2014-10-27
- **Final completion:** 2017-10-19
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2019-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328249, "Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01328249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*